What Is Ovarian Cancer?

Ovarian cancer is a malignant disease originating in the tissues of the ovaries, fallopian tubes, or the lining of the abdominal cavity. It encompasses several histologically and molecularly distinct subtypes, the most lethal of which is high-grade serous carcinoma, which accounts for roughly 70 percent of all ovarian cancer deaths. The disease is characterized by late-stage presentation: most patients are diagnosed at Stage III or IV, when the tumor has spread beyond the pelvis into the peritoneal cavity and lymph nodes. At this stage, the five-year survival rate is approximately 30 to 40 percent, a figure that has improved only modestly despite decades of treatment advances. Early-stage disease, when confined to the ovary, carries a five-year survival exceeding 90 percent, motivating sustained research into detection and screening strategies.

Ovarian cancer draws on research spanning oncology, genetics, molecular biology, and biomedical engineering. Imaging technologies, biosensor development, and machine learning-based diagnostic tools all contribute to the effort to shift diagnoses to earlier, more treatable stages.

Pathology and Molecular Subtypes

Ovarian cancers are classified by cell type of origin into epithelial, germ cell, and sex cord-stromal tumors, with epithelial cancers comprising about 90 percent of cases. High-grade serous carcinoma, the dominant epithelial subtype, is now understood to originate primarily in the fimbriated end of the fallopian tube rather than the ovarian surface epithelium. A consensus framework described in research on molecular subtypes of high-grade serous ovarian carcinoma identifies four subtypes: mesenchymal, immunoreactive, differentiated, and proliferative, each with distinct expression profiles and prognoses. BRCA1 and BRCA2 mutations are present in 20 to 25 percent of high-grade serous cases and confer sensitivity to PARP inhibitor therapy, making germline and somatic genetic testing a routine part of management. Clear cell and endometrioid subtypes are associated with endometriosis and carry a different therapeutic profile from the serous disease.

Diagnosis and Biomarkers

Ovarian cancer has no validated screening test for the general population. Transvaginal ultrasound and serum CA-125 measurement are the primary tools for evaluating women with symptoms or elevated risk, but both have limited specificity when used independently. CA-125 is elevated in fewer than 50 percent of early-stage cases and is also elevated in benign conditions including endometriosis and uterine fibroids. Research on AI-based ovarian cancer identification across imaging modalities found that machine learning algorithms achieved pooled sensitivity of 88 percent and specificity of 85 percent across 28 studies, with ultrasound-based AI reaching an AUC of 0.95. Novel liquid biopsy approaches, including detection of circulating tumor DNA and cancer-specific metabolite signatures, are under investigation as candidates for earlier detection. A Nature Biomedical Engineering study demonstrated detection of high-grade serous carcinoma in serum using quantum-defect-modified carbon nanotubes with machine learning classification, achieving 87 percent sensitivity at 98 percent specificity.

Treatment and Surgical Staging

Treatment for epithelial ovarian cancer follows a combination of cytoreductive surgery and platinum-based chemotherapy. Surgical staging assigns disease to Stages I through IV based on the anatomical extent of spread, and the quality of cytoreduction, measured as the volume of residual disease after surgery, is one of the strongest predictors of outcome. First-line chemotherapy typically combines carboplatin with paclitaxel for six cycles. PARP inhibitors including olaparib and rucaparib are approved for maintenance therapy in BRCA-mutated and homologous recombination-deficient tumors, reducing the risk of recurrence after initial response.

Applications

Ovarian cancer research intersects with biomedical engineering and technology across several areas, including:

• Medical imaging analysis using deep learning for tumor segmentation and staging
• Biosensor and liquid biopsy development for early detection of circulating biomarkers
• Surgical robotics and laparoscopic tools for minimally invasive cytoreduction
• PARP inhibitor and targeted drug delivery research for homologous recombination-deficient tumors
• Genomic sequencing platforms for BRCA and somatic mutation profiling